Phase 4 N=128 Supportive Care

Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test

Skin Irritation

Bottom Line

View on ClinicalTrials.gov: NCT01892657 ↗

Enrolled (actual)

128

Serious AEs

0.0%

Results posted

Sep 2013

Primary outcome: Primary: Area of Erythema and Elevated Responses of Skin to Product — 91; 68; 33; 42 participants

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Facial Moisturizer with SPF 50+ (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Galderma R&D
Primary completion: May 2008

Outcome Measures

Outcome	Result	p-value
PRIMARY Area of Erythema and Elevated Responses of Skin to Product	91; 68; 33; 42; 39; 20	—

Summary

This study examined the possible sensitization and irritation effects of a moisturizer with sunscreen SPF 50+.

Eligibility Criteria

Inclusion Criteria

Men or women 18 to 70 years of age in general good health
Can read, understand, and sign informed consent

Exclusion Criteria

History of acute or chronic disease
Diagnosed with chronic skin allergies
Pregnant or lactating

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01892657). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.